Dong-A Socio Holdings Co., Ltd. (000640)

Overview

Dong-A Socio Holdings Co., Ltd. is a prominent entity in the pharmaceutical domain, both within South Korea and on a global scale. Founded in 1932, the company has its headquarters in Seoul, South Korea. It is reputed for its significant contributions to pharmaceutical research and development, particularly focusing on various therapeutic areas including type 2 diabetes, obesity, overactive bladder, anemia, HIV-1, and cancer, among others. Besides its core pharmaceutical business, Dong-A Socio Holdings extends its expertise into healthcare solutions, CDMO services, production of imaging equipment, mineral water, and also ventures into IT and construction services.

Products and Services

• DA-1241 - A groundbreaking development aimed at treating type 2 diabetes and non-alcoholic steatohepatitis.
• DA-1726 - An oxyntomodulin analogue for obesity treatment, showcasing the company's dedication to addressing metabolic disorders.
• DA-1229 - A dipeptidyl peptidase-4 inhibitor, reflecting the company's innovation in diabetes management.
• DA-8010 - A muscarinic M3 receptor antagonist developed for the treatment of overactive bladder, highlighting the company's focus on improving quality of life.
• DMB-3115 - A biosimilar of Stelara, targeted at inflammatory disease treatment, demonstrating the company's competence in biosimilars.
• DA-3880 - An innovative solution for anemia treatment, underpinning the firm's dedication to comprehensive healthcare.
• STP0404 - An HIV-1 treatment drug, indicative of the company's contribution to infectious disease therapeutics.
• STP1002 - An anti-cancer drug, showcasing the company's commitment to oncology and the development of life-saving medications.
• Healthcare Solutions - Provides an array of healthcare solutions in Bacchus, over-the-counter, consumer healthcare, and derma business areas, reflecting its diverse approach to healthcare.
• CDMO Services - Offers Contract Development and Manufacturing Organization services, underlining its versatility in pharmaceutical manufacturing.
• Imaging Equipment and ENT Workstation Products - Develops medical imaging equipment and ENT workstation products, leveraging its technological capabilities in medical devices.
• Mineral Water - Markets mineral water under the Cheonnyeonsu brand name, expanding its business into consumer goods.
• IT and Construction Services - Engages in IT and construction services, illustrating the company's multi-dimensional business model.
• Glass Bottles, PET, and Corrugated Cardboard Boxes Production - Produces packaging materials, demonstrating its operational diversity and commitment to sustainability.
• Foundry Equipment, Logistics, and Food and Beverage Businesses - Participates in a variety of sectors, highlighting its broad business interests and ability to innovate across industries.